Doxorubicin pharmacokinetics in lymphoma patients treated with doxorubicin-loaded eythrocytes

Haematologica

Volumn 92, Issue 4, 2007, Pages 570-571

  Skorokhod, Oleksii A ^a,b   Kulikova, Elena V ^a   Galkina, Ninel M ^a   Medvedev, Pavel V ^a   Zybunova, Elena E ^a   Vitvitsky, Victor M ^a   Pivnik, Aleksandr V ^a   Ataullakhanov, Fazoil I ^a  

^a NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Carrier erythrocytes; Doxorubicin; Lymphoma; Pharmacokinetics

Indexed keywords

DOXORUBICIN; ABVD PROTOCOL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN; CHOP PROTOCOL; CYCLOPHOSPHAMIDE; DACARBAZINE; DRUG CARRIER; PREDNISONE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA; MALE; BLOOD AUTOTRANSFUSION; ERYTHROCYTE TRANSFUSION; LETTER; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BLOOD TRANSFUSION, AUTOLOGOUS; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; DRUG CARRIERS; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PREDNISONE; VINBLASTINE; VINCRISTINE;

EID: 34547682311     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10770     Document Type: Article

References (8)

1. Magnani M, Rossi L, Fraternale A, Bianchi M, Antonelli A, Crinelli R, et al. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther 2002; 9:749-51.
2. Rossi L, Serafini S, Pierige F, Antonelli A, Cerasi A, Fraternale A, et al. Erythrocyte-based drug delivery. Expert Opin. Drug Deliv 2005;2:311-22.
3. Ataullakhanov FI, Kulikova EV, Vitvitsky VM. Doxorubicin binding by human erythrocytes. Adv Biosci 1994;92:163-8.
4. Skorokhod OA, Garmaeva TTs, Vitvitsky VM, Isaev VG, Parovichnikova EN, Savchenko VG, et al. Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia. Med Sci Monit 2004; 10:PI55-PI64.
5. Matherne CM, Satterfield WC, Gasparini A, Tonetti M, Astroff AB, Schmidt RD, et al. Clinical efficacy and toxicity of doxorubicin encapsulated in glutataldehyde treated erythrocytes administered to dogs with lymphosarcoma. Am J Vet Res 1994;55:847-53.
6. Tonetti M, Zocchi E, Guida L, Polvani C, Benatti U, Biassoni P, et al. Use of glutaraldehyde treated autologous human erythrocytes for hepatic targeting of doxorubicin. Adv Exp Med Biol 1992;326:307-17.
7. Ataullakhanov FI, Isaev VG, Kohno AV, Kulikova EV, Parovichnikova EN, Savchenko VG, et al. Pharmacokinetics of doxorubicin in patients with lymphoproliferative disorders after infusion of doxorubicin-loaded erythrocytes. In: Sprandel U, Way JL, editors. Erythrocytes as Drug Carriers in Medicine. New York, London: Plenum Press; 1997. p 137-42.
8. Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 1993;17:219-52.